Twist Bioscience - TWST Stock Forecast, Price & News

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.

Twist Bioscience Price Performance

TWST Stock traded up $0.94 during trading on Monday, hitting $53.91. 721,970 shares of the stock traded hands, compared to its average volume of 1,067,215. Twist Bioscience has a 1 year low of $25.07 and a 1 year high of $139.99. The firm's 50 day moving average is $40.29 and its two-hundred day moving average is $42.99. The stock has a market cap of $3.04 billion, a price-to-earnings ratio of -13.61 and a beta of 1.19.

Twist Bioscience (NASDAQ:TWST - Get Rating) last announced its quarterly earnings results on Friday, August 5th. The company reported ($1.08) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.31) by $0.23. The firm had revenue of $56.10 million for the quarter, compared to the consensus estimate of $52.06 million. Twist Bioscience had a negative net margin of 112.91% and a negative return on equity of 29.61%. The business's quarterly revenue was up 60.3% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.82) EPS. As a group, analysts anticipate that Twist Bioscience will post -4.53 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on TWST shares. Robert W. Baird lifted their price target on Twist Bioscience from $43.00 to $56.00 in a research report on Monday, August 8th. SVB Leerink increased their target price on Twist Bioscience from $45.00 to $50.00 and gave the stock a "market perform" rating in a research note on Monday, August 8th. Finally, Barclays upped their price target on shares of Twist Bioscience from $45.00 to $55.00 and gave the stock an "overweight" rating in a research note on Monday, August 8th.

Insider Activity

In other news, CFO James M. Thorburn sold 6,620 shares of the firm's stock in a transaction dated Friday, May 20th. The shares were sold at an average price of $36.02, for a total transaction of $238,452.40. Following the sale, the chief financial officer now owns 45,386 shares of the company's stock, valued at approximately $1,634,803.72. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, CFO James M. Thorburn sold 6,620 shares of the firm's stock in a transaction dated Friday, May 20th. The shares were sold at an average price of $36.02, for a total transaction of $238,452.40. Following the sale, the chief financial officer now owns 45,386 shares of the company's stock, valued at approximately $1,634,803.72. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider William Banyai sold 1,275 shares of the firm's stock in a transaction dated Monday, May 23rd. The shares were sold at an average price of $37.04, for a total transaction of $47,226.00. Following the sale, the insider now directly owns 259,926 shares in the company, valued at approximately $9,627,659.04. The disclosure for this sale can be found here. Insiders have sold a total of 19,581 shares of company stock valued at $654,504 in the last 90 days. 3.10% of the stock is currently owned by insiders.